Ep. 1: Overcoming Infusion Barriers in EGFR-Mutant Non–Small Cell Lung Cancer
Key Points
-
Amivantamab plus lazertinib (MARIPOSA) defines the standard of care for EGFR-mutant non–small cell lung cancer (NSCLC).
-
Strong survival outcomes support the MARIPOSA regimen.
-
Infusion reactions associated with intravenous amivantamab are manageable and differ fundamentally from life-threatening cytokine release syndrome seen with T-cell–engaging bispecific antibodies.
In a discussion on the evolving treatment landscape in EGFR-mutant NSCLC, Chinmay Jani, MD, of the University of Miami, and Luis Raez, MD, FACP, FCCP, FASCO, of Memorial Healthcare System, examined the clinical implications of the approval of subcutaneous amivantamab. Dr. Raez emphasized that clinicians now have two frontline standards for EGFR-mutant disease: chemotherapy plus osimertinib (FLAURA2) and amivantamab plus lazertinib (MARIPOSA).
Despite strong progression-free and overall survival data supporting the MARIPOSA regimen, community uptake has been slower, largely due to concerns about infusion-related reactions. Dr. Raez contextualized these concerns by comparing amivantamab with hematologic bispecific antibodies that engage T cells and can cause life-threatening cytokine release syndrome (CRS).